Streetbeat News

Analyst Ratings

SPRO

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:40 am

OPGN

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on OpGen (NASDAQ:OPGN) and maintained a price target of $3.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:38 am

AAPL

Citigroup analyst Atif Malik has reiterated a 'Buy' rating on Apple (NASDAQ:AAPL) and maintained a price target of $240.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:38 am

TRX

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on TRX Gold (AMEX:TRX) and raises the price target from $1.1 to $1.3.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:37 am

WAL

JP Morgan analyst Steven Alexopoulos maintains an Overweight rating on Western Alliance (NYSE:WAL) and raises the price target from $53 to $60.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:35 am

HAL

JP Morgan analyst Arun Jayaram maintains an Overweight rating on Halliburton (NYSE:HAL) but lowers the price target from $50 to $45.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:34 am

VZIO

Needham analyst Laura Martin has reiterated a 'Buy' rating on VIZIO Holding (NYSE:VZIO) and maintained a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:34 am

DSP

Needham analyst Laura Martin has reiterated a 'Buy' rating on Viant Technology (NASDAQ:DSP) and maintained a price target of $7.5.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 10:33 am

DHI

D.R. Horton (NYSE:DHI) reported Q3 earnings of $3.90 per share, beating the analyst consensus estimate of $2.79 by 39.78%. However, this is a 16.49% decrease from the same period last year. The company also reported quarterly sales of $9.72 billion, beating the analyst consensus estimate of $8.39 billion by 15.91%, and marking a 10.66% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:33 am

APLS

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowered the price target from $100 to $72.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 10:32 am